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Abstract  
 
Introduction: The ‘Use of a Multi-drug Pill in Reducing cardiovascular Events’ (UMPIRE) trial 
was a randomised controlled clinical trial evaluating the impact of a polypill strategy on 
adherence to indicated medication in a population with established cardiovascular disease 
of or at high risk thereof. The aim of RUPEE-NHS is to estimate the potential health 
economic impact of a polypill strategy for CVD prevention within the NHS using UMPIRE trial 
and other relevant data.  This paper describes the design of a modelled economic evaluation 
of the impact of increased adherence to the polypill versus usual care amongst the UK 
UMPIRE participants.   
 
Methods and Analysis: As recommended by ISPOR-SMDM modelling guidelines a review of 
published CVD models was undertaken to identify the most appropriate modelling approach 
and structure.  The review was carried out in the electronic databases, MEDLINE and 
EMBASE. 40 CVD models were identified from 57 studies, the majority of economic models 
were health state transition cohort models and individual level simulation models. The 
findings were discussed with clinical experts to confirm the approach and structure. An 
individual simulation approach was identified as the most suitable method to capture the 
heterogeneity in population CVD risk.  RUPEE-NHS will use UMPIRE trial data on adherence 
to estimate the long term cost-effectiveness of the polypill strategy.  
 
Dissemination: The evaluation findings will be presented in open access scientific and 
healthcare policy journals and at national and international conferences.  We will also 
present findings to NHS policy makers and pharmac utical companies.   
 
 
 
Strengths and Limitations 
This paper provides a clear outline of how a model for an economic evaluation is developed. 
 
Providing an outline of the model structure which includes details on the underlying 
epidemiology and data inputs will add transparency to the findings of the RUPEE-NHS study  
 
Though the model has been designed to include all major adverse and beneficial effects of 
treatment, the model structure will not include every potential treatment effect, for 
example the benefits of treatment on Alzheimer's disease will not be included. 
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INTRODUCTION 
Adherence to recommended preventive medication regimes (1,2) in people at high risk of 
cardiovascular disease (CVD) is low, even in high income countries. (3)  Poor adherence is associated 
with greater deterioration in health status and increased health care costs (4) and studies have 
shown that improved adherence to medication is associated with clinical benefits.(5)  CVD 
preventive medication typically involves several drugs and adherence is inversely proportional to the 
number of prescriptions.   Furthermore, physician inertia and patient resistance present barriers to 
initiating or restarting full recommended therapy. A single pill that includes several indicated drugs 
(a “polypill”), may improve long-term adherence by addressing these issues.  If the polypill is priced 
lower than the price of the pills bought separately, it will also make it more affordable. (6,7)  The 
UMPIRE (Use of a Multidrug Pill in Reducing Cardiovascular events) clinical trial was set up to 
evaluate the polypill in patients with or at high risk of CVD.   
 
The UMPIRE trial randomised 2004 participants with established CVD (prior CVD event such as 
stroke or myocardial infarction) or at high risk of CVD (defined as a 5 year risk of >15%) based in 
India, England, Ireland and The Netherlands to either the polypill or usual care.  The primary 
outcome of the trial was adherence to indicated treatments (statin, aspirin and two blood pressure 
lowering drugs), measured as self-reported current use of antiplatelet, statin and ≥2 blood 
pressure lowering therapies for at least 4 days in the week preceding visits (baseline and 
end of trial visits).  Other outcomes included systolic blood pressure (SBP) and low-density 
lipoprotein cholesterol (LDL-C). The trial found that the use of a polypill strategy resulted in greater 
adherence to treatment at 15 months and significant improvements in SBP and LDL-C.  Detailed 
results and a description of the UMPIRE trial protocol are available. (8, 9)  
 
UMPIRE collected data on resource use and self-reported health related quality of life using the EQ-
5D.  In order to estimate the long term costs and health outcomes associated with the polypill 
strategy an economic model is required.   Due to differences in the patient population, care pathway 
and health care costs, separate analyses are needed for the four participating countries.   
 
The analysis of the UMPIRE English trial data, (Researching the UMPIRE Processes for Economic 
Evaluation in the National Health Service (RUPEE-NHS)), aims to estimate the cost-effectiveness of 
the polypill strategy compared to conventional multi-drug therapy for the prevention of established 
cardiovascular disease in English NHS patients with or at high risk of CVD.  The RUPEE (NHS) study 
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will use UMPIRE English trial data on adherence to the polypill and will develop an economic model 
to estimate cost effectiveness.  
 
The aim of this paper is to detail the modelling plan for the RUPEE (NHS) study.    
METHODS 
Model design process  
An economic model has been described as a mathematical framework that represents reality at an 
adequate level of detail to inform clinical or policy decisions. (10)  Guidelines on modelling produced 
by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the 
Society for Medical Decision Making (SMDM) joint taskforce recommend that it is best practice to 
carry out a conceptualisation process prior to programming the economic model.  This process has 
two distinct components: specification of the study question and economic model. (11)   
Specification of the study question 
The first component informs choices about how to structure the economic model and parameters.    
The RUPEE (NHS) study aims to evaluate two different treatment strategies in a population with or 
at high risk of CVD.   The population for the economic model is defined by the inclusion criteria of 
the UMPIRE trial.  (9)  The inclusion criteria are listed below: 
 
• Aged ≥18 years and 
• High CVD risk defined as either established atherothrombotic CVD (history of coronary heart 
disease (CHD), ischaemic cerebrovascular disease, or peripheral arterial disease (PAD)) or a 5 
year risk of ≥15% calculated using the Framingham risk equation  
 
The economic model will evaluate the polypill strategy compared to usual medication. In the 
UMPIRE trial, participants assigned to the polypill received one of 2 versions: version 1 contained 
aspirin 75mg, simvastatin 40mg, lisinopril 10mg and atenolol 50mg, and version 2 contained the 
same ingredients but substituted hydrochlorothiazide 12.5mg for atenolol 50mg.  Participants 
assigned to usual care continued taking medications as prescribed by their general practitioner (GP).   
 
The RUPEE (NHS) study will follow guidelines for modelling health technologies as recommended by 
the National Institute for Health and Care Excellence. (NICE) (12) Therefore a NHS and Personal 
Social Services (PSS) perspective will be adopted to measure health service resource use and health 
related quality of life will be measured by quality adjusted life years (QALYs) obtained using the EQ-
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5D.  As per the NICE guidelines, costs and QALYS will be discounted at a rate of 3.5% per year.  (12) 
The time horizon reflected in the economic model will be lifetime to represent the chronic nature of 
CVD.  
Conceptualisation of the economic model 
The second component of the conceptualisation process involves defining the economic model.  
There are two steps to this approach.  The first step is to identify the appropriate modelling 
approach.  The modelling approach defines the analytical framework of the economic model.  
Different types of analytical frameworks have been used to represent CVD including decision trees, 
state transition models, compartmental models, individual simulation models and hybrid models 
which often combine elements from different frameworks.  (13-17) 
 
The second step determines the underlying structure of the analytical framework, which will 
represent the disease and care pathway.  The modelling approach needs to reflect: 1) CVD disease 
and care pathway for this population; 2) the beneficial and adverse effect of treatment (polypill or 
usual care); 3) the impact of increased adherence to treatment on health outcomes.   
 
The guidelines produced by ISPOR-SMDM on modelling recommend that existing models addressing 
related problems should be reviewed as this approach can help identify both the modelling 
approach and underlying structure.(11) To inform the RUPEE (NHS) economic model, we carried out 
a review of published models evaluating interventions for CVD.   
 
Review of published CVD economic models  
The purpose of the literature review was to identify the appropriate analytical framework to 
represent the decision problem.  The literature review also aimed to inform the underlying model 
structure: disease and care pathway.  
Search strategy 
The search strategy was conducted using the NHS Economic Evaluation Database (NHS EED), the 
NIHR Health Technology Assessment (HTA) monograph series and the NICE guidelines website.  The 
search terms used included ‘cardiovascular disease’, ‘coronary heart disease’, ‘stroke’, ‘myocardial 
infarction’, ‘angina’ and ‘peripheral artery disease’.  Studies were excluded from the review if they 
did not discuss the development or review of an economic model; if no disease states for 
cardiovascular disease were included in the model; if the focus of the study was a diagnostic test or 
surgical intervention where the economic model used a time frame of <10 years.  Studies were not 
excluded on the basis of intervention (drug treatment or lifestyle intervention) or on the basis of 
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date published or language.   We developed a data extraction form which included fields on model 
purpose, structure, health states and events, transparency and validation.   We did not collate 
information about the findings of the model as the objective of the review was to identify alternative 
model frameworks and methods used to represent CVD.  
 
An initial general literature search identified a 2006 systematic review of CHD policy models by Unal 
et al. which was updated in 2008 by Capewell et al. and expanded to include stroke models. (17,18)  
The review by Capewell et al. identified seven ‘notable’ CHD models (of which six had been 
identified in the previous review by Unal et al.), nine stroke models and several models that were 
currently in development at the time of publication.  We reviewed the notable models and models in 
development identified by Capewell et al.   Citation searching of both systematic reviews was carried 
out to identify other models published since 2008. 
Review findings 
Overall 57 studies were identified which reported on 40 CVD models.  Figure 1 presents the 
flowchart for the search strategy.   
The search found several studies which reported on the same model, for example the IMPACT CHD 
model developed by Capewell et al. was used in analyses of CVD in other populations. (19)  In some 
cases, a model was adapted for different analyses, such as the Sheffield model which was developed 
to evaluate statin therapy and was then adapted for use in the development of the NICE guidelines 
for lipid modification. (1,20) The Sheffield model was also partially used in a whole population 
modelling study by Barton et al. (13)    
Further details on the review can be found in the supplementary appendix.  The appendix includes a 
list of the reviewed models (see Table 1 supplementary appendix), an example of the data extraction 
form and an example of an illustration and details of one of the reviewed models (see Figure 1 
supplementary appendix).  Schematic illustrations of several models were used in discussions with 
clinical experts about the different types of modelling approaches 
 
[Figure 1- Flowchart for search strategy for CVD models] 
Modelling approach  
The search identified that the two most commonly used modelling approaches were health state 
transition cohort models and individual-level simulation models.  Both approaches were critically 
assessed to determine their suitability to capture the disease and care pathway.  
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A cohort model can be defined as any model which estimates the outcomes for a group of patients, 
whereas with a patient level simulation, outcomes are evaluated at the individual level.  Therefore, 
one of the main differences between the two approaches is how they estimate costs and QALYs: 
cohort models estimate expected costs and QALYs for the modelled population as a whole, whereas 
individual level simulation models estimate cost and QALYs for each individual and the average is 
taken across the sample.  
 
With a health state transition cohort model, the population progresses through a set of mutually 
exclusive health states at regular intervals called cycles, determined by a predefined transition 
matrix.  Health state transition cohort models are also commonly called Markov models.  However, 
such models are only Markovian when they display the Markovian ‘memoryless’ property where the 
progression of the patient through the model is only dependent on the current state in which the 
patient resides and not on anything that happened before they entered that health state.   It is also 
possible to model at the individual level using a state transition model by sampling probabilities for 
each individual patient to experience a particular transition in each model cycle. (21) 
 
Both model approaches can use a discrete time approach: with this approach the model cycle length 
will be defined in advance.  The cohort or individual progress through health states or events which 
represent the disease pathway and only one event may occur within each cycle length.  Costs and 
QALYs are updated once per cycle.  Alternatively, individual level simulation models are often set up 
as discrete event simulations (DES).  With a DES approach, an event can occur at any time point, for 
example, an event could occur at three months, one year and twenty years.  As an event occurs, 
costs and QALYs are recorded and updated for each individual.  
 
A health state transition model was used to develop NICE guidance for lipid modification treatment. 
(1) The limitation of this approach is that it may be unable to capture the underlying heterogeneity 
in the population.  Individual CVD risk can be estimated using CVD risk algorithms such as QRISK2 
which use a range of patient characteristics such as age, sex, ethnicity, systolic blood pressure and 
body mass index to estimate a 10 year CVD risk.(22)  To capture this complexity in a health state 
transition model would require the construction of a large number of subgroups to reflect different 
subsets of patient characteristics and the variation in CVD risk in the population.  This could become 
impractical to model.  It also has the disadvantage that accuracy could be lost by using 
representative values for subgroups.  An individual simulation model structure may be more 
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appropriate to model the level of detail required to estimate CVD outcomes reflective of those in the 
population.   
 
The Markovian memoryless property means that data on individual patients’ history is not 
retained as they progress through the model.  Accounting for individual patient history in a 
Markov model would require multiplying the number of health states to an infeasible level 
where the model would become too complex and impracticable to run. 
 
To accurately identify the effectiveness of each treatment strategy in a population with or at high 
risk of CVD, an individual simulation model was deemed the most appropriate for the RUPEE (NHS) 
study to reflect the heterogeneity in the population which impacts on the risk of a CVD event and 
subsequent costs and outcomes.  The individual simulation model will use a discrete event approach 
to handle time.(21) 
Model structure  
The findings of the review were discussed with clinical experts to confirm the health events and the 
methods used to model the progression of persons through the disease pathway.   
Model events (CVD, diabetes and adverse events) 
The most commonly included types of CVD events in the reviewed models were CHD (angina and 
myocardial infarction), cerebrovascular events (transient ischaemic attack (TIA) and stroke) and 
peripheral arterial disease (PAD).  It was decided that the CVD events relevant for the current model 
would reflect those most commonly included in prior such models.  PAD will not be included as a 
CVD event in the model as there is less likely to be a definable acute PAD event compared to other 
CVD events such as MI and stroke.  We will assume that patients can experience more than one CVD 
event in their lifetime.  The risk of CVD will also be assumed to change with age in the model.   
 
Diabetes is a risk factor for CVD with a substantial cost and impact on health related quality of life, 
therefore diabetes will be included as a comorbidity in the model.   The risk of new onset diabetes 
will be estimated using the QDiabetes risk algorithm.(23)   
 
Adverse effects from treatment will include an increase in the risk of new onset diabetes resulting 
from treatment with statins and antihypertensive drugs.  (24-27)  The risk of a persistent cough 
resulting from treatment with angiotensin-converting-enzyme inhibitors (ACE inhibitors) will be 
included as an event.  The probability of a cough resulting from treatment will be sourced from 
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meta-analyses of randomised controlled trial (RCT) data for ACE inhibitors. As aspirin use is 
associated with an increased risk of gastrointestinal bleeding,(28,29) an increased risk of 
gastrointestinal bleeding from treatment with aspirin will be included.  
 
Renal impairment will not be included in the model as an adverse effect of ACE inhibitors. Whilst 
ACE inhibitors may cause an acute rise in serum creatinine in a few patients with renal artery 
stenosis and more generally cause a slight short term increase in creatinine levels, the effects are 
complex and there may be a net improvement in renal function overall in a treated population.  The 
rate of falls and fractures will be estimated not to alter, given the evidence from randomised trials of 
blood pressure lowering agents, although this is an area of debate with regard to patients with 
higher levels of frailty.  (30, 31)    
 
Other adverse effects from statin treatment such as liver dysfunction and myopathy will not be 
included in the model as these cases are rare and are assumed to have a minimal impact on 
outcomes. (1) (32)   
 
Treatment with antihypertensives is associated with a reduction in heart failure, therefore this will 
be included as an outcome in the model. (33)   Other outcomes of treatment are likely but will not 
be included – for example a reduction in cancer with aspirin use of more than 5 years. (34)   
 
Progression of individuals through model   
The progression of persons through the disease pathway differs depending on the modelling 
approach: health state transition models such as the Markov model developed for NICE guidelines 
on lipid modification use a predefined transition matrix to determine progression through the CVD 
health states.(35) Alternatively, simulation models can use risk algorithms to estimate the 
probability of CVD events or new onset diabetes.  The NICE guidelines for lipid modification 
recommend the use of QRISK2, which is a risk algorithm derived to estimate primary CVD risk in UK 
populations. (1,22)  The QRISK2 risk algorithm predicts the risk of a 10 year CHD event (angina, MI) 
or a cerebrovascular event (TIA, stroke).  It does not include the risk of PAD.  An alternative CVD risk 
algorithm is the Framingham equation;(36), however, a validation study comparing QRISK2 and 
Framingham found that QRISK2 is better calibrated to a UK population.(37)  The RUPEE (NHS) model 
will therefore use the QRISK2 risk algorithm. 
Page 9 of 66
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
10 
 
RUPEE (NHS) economic model  
Figure 2 depicts the flowchart of the RUPEE (NHS) model structure.  The oval shapes represent data 
inputs to the model, whereas the rectangular shapes represent processes.  
 
[Figure 2 - Flowchart of RUPEE (NHS) model structure] 
Model description  
In the RUPEE (NHS) model costs and QALYs are recorded for each individual and an average cost and 
QALY for the simulated population are estimated.  The RUPEE (NHS) model will be run twice, once to 
simulate costs and QALYs under usual care and once to simulate costs and QALYs under the polypill 
scenario (polypill scenario will include polypill version 1 and version 2).  Individuals representing the 
UMPIRE trial inclusion criteria will enter the model (label 1 in Figure 2), and their baseline risk of a 
CVD event and onset diabetes will be estimated using the QRISK2 CVD risk algorithm and QDiabetes 
algorithm (label 2 in Figure 2) respectively.  For each individual, whether or not they are adherent to 
medication will be simulated using Monte Carlo simulation based on the probability of adherence in 
usual care (label 3a in Figure 2).  If the individual is simulated to be adherent to medication their risk 
of a CVD event will be modified by a treatment effect (label 4 in Figure 2).  In the polypill scenario of 
the model, the probability of adherence will be further modified by the relative risk of adherence to 
medication.   The relative risk of adherence to medication will be sourced from the UMPIRE trial data 
(label 3b in Figure 2).  Individuals may experience a CVD event or onset of diabetes based on their 
estimated CVD and diabetes risk, which will be estimated using the QRISK2 and QDiabetes 
algorithms.   Individuals may also experience an adverse reaction to medication (if adherent) 
including gastrointestinal bleeding, early onset of diabetes and a persistent cough.  Costs and QALYs 
will be recorded for each event (including adverse events).   Individuals can experience more than 
one event (model run for lifetime horizon) and patient characteristics such as age and history of 
previous events, such as a stroke or new onset diabetes, are updated during the model run, with an 
ensuing reflective increase in the risk of an event.  
Input parameters  
Each point in the flowchart is labelled and a description of the process or data requirement label is 
described below.  Table 1 provides further details on data input parameters for the RUPEE-NHS 
model and potential sources of data. 
 
1. Population Dataset   
We will use the 2011 Health Survey for England (HSE) as a population dataset for the economic 
model.  The HSE is a cross sectional survey which contains anonymised information on a 
representative sample of the population.  The 2011 HSE dataset collected information on CVD, 
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including individual CVD events and medication history. The dataset also contains information on 
demographic and socio-economic characteristics and health related data such as body mass index 
(BMI), SBP and LDL-C and history of CVD events.  These data are required in order to estimate 
individual baseline risks of CVD and diabetes in the model.   
 
2. Calculation of baseline risks of events without treatment 
Baseline risks for CVD for each sampled individual will be calculated using published risk algorithms.  
As per recent NICE guidance for lipid modification, we will use the recommended algorithm for CVD 
risk, QRISK2.  (1,22)   The algorithm was derived using QRESEARCH, a large database derived from 
the pseudonymised health records of over 13 million patients registered with a general practitioner 
in the UK.  If an individual has established CVD (previously experienced a CVD event), we will 
estimate a secondary CVD risk using the REACH algorithm. (38) A baseline risk for the onset of 
diabetes will be estimated using the QDiabetes algorithm. (23)   
 
3a. Simulating adherence to treatment under usual care  
The RUPEE study will evaluate the effect of adherence to medication on long term costs and health 
outcomes measured using quality adjusted life years (QALYS).  The average rates of adherence in 
clinical trials can be higher than in actual practice (4) as seen in the UMPIRE clinical trial population 
which had an atypically high baseline adherence rate.  Instead, adherence rates to medication 
(antihypertensives, statins and aspirin) under a usual care setting will be sourced from the 2011 HSE 
dataset.  Participants in the 2011 HSE self-reported all the prescribed medications they had taken in 
the last 7 days.  This was coded in the HSE dataset using the British National Formulary (BNF) 
classifications codes.  Using this data, we are able to identify the medication patients were 
prescribed and identify whether or not they were taking the prescribed medication in the last week.  
This will reflect adherence to medication in a usual care population.  The data will be used to 
estimate the probability of each person being adherent or not to medication.  Individual 
characteristics will be used as predictors of adherence; the characteristics will be chosen by referring 
to studies which have assessed predictors of adherence in persons taking treatment for CVD. (39, 
40) A generalized linear mixed regression model will be used to estimate the probability of 
adherence to medication for each individual.  The probability of persistence with medication will not 
be assumed to be constant, and the model will include a probability of ceasing medication over time.  
The probability of medication cessation will be sourced from published literature on adherence.  
 
3b. Estimate relative risks of adherence to medication  
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We will estimate the relative risks of adherence to medication, using a generalised linear mixed 
regression model which will be applied to the UMPIRE trial dataset (UK dataset).  In the polypill 
scenario in the model, the probability of being adherent to medication will be further modified by 
the relative risks.  
 
4. Adjust risk of events for treatment  
We will source data on the treatment effects of statins, antihypertensives and aspirin from meta-
analyses of intention-to-treat RCTs.  Intention-to-treat analyses account for non-adherence in their 
findings, and therefore underestimate the impact of treatment on event risk.  To overcome this, we 
will carry out sensitivity analyses to test the impact of adjusting for adherence within the trial.   The 
risk of a CVD event will be adjusted by the relative risk of treatment with statins, antihypertensives 
and aspirin, based on the medication(s) the person is taking and whether or not they are adherent to 
medication. 
 
5. Simulation of events 
Individuals in the model can experience a CVD event at a rate governed by their calculated baseline 
risk (estimated by the QRISK2 or REACH algorithms) and adjusted for treatment effects if they have 
been simulated as adherent to treatment.  CVD events will be categorised as a TIA, stroke, MI or 
angina.  The relative incidence of each CVD event will be determined using published incidence 
data.(41)  Similarly, the risk of new onset diabetes will be calculated using the QDiabetes algorithm.  
We will simulate the incidence of adverse events as a result of treatment: new onset diabetes and 
gastrointestinal bleeds.   Data on the probability of an adverse event will be sourced from meta-
analyses of randomised controlled trials for the relevant drugs.  Mortality risk will be modelled as 
mortality from stroke and MI and other cause mortality.  Data on other cause mortality will be 
estimated using national life tables for England and Wales. (42) 
 
6. Assign cost and quality of life values 
Costs and QALYs associated with each individual’s simulated lifetime profile of CVD and related care 
will be estimated.  Costs and quality adjusted life years (QALYs) will accrue for each person to reflect 
events, such as a stroke or new onset diabetes.  Costs and utility values for health events will be 
sourced from published studies including the NICE guidelines for lipid modification and 
hypertension. (1,35,43)  Costs of medication will be sourced from the NHS National Drug Tariff.(44) 
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7. Change in age, treatment, CVD status and type II diabetes status 
The simulation model will run for each individual for lifetime duration (death or maximum age of 
100 years) and patient characteristics will be updated after each event or every 10 years (depending 
on which event occurs first).  A 10 year update is used as the QRISK2 algorithm returns a 10 year CVD 
risk.  
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Table 1) Input parameters  
Model inputs Source   
1. Individual dataset    
Population dataset Initial patient characteristics (see Figure 2) for cohort of patients 
drawn from a representative national sample: Health Survey for 
England (HSE) dataset 2011.  The dataset will include patients who 
meet the entry criteria for the UMPIRE trial. 
2. Calculation of baseline risks   
Risk calculators  
 
 
 
 
 
 
 
 
 
 
 
 
Risk of heart failure 
Risk of first CVD event and onset of type 2 diabetes estimated for 
individuals using QRISK2 and QDiabetes.(23, 24) 
 
QRISK2:  10 year CVD risk (CVD outcomes defined as angina, MI, TIA 
and stroke) 
QDiabetes: risk of acquiring type 2 diabetes over 10 year time period 
 
Risks for subsequent CVD events estimated for individuals using the 
REACH algorithm.  (38) 
CVD outcomes defined as cardiovascular death (includes fatal stroke 
and MI), non-fatal MI, non-fatal stroke, and cardiovascular 
hospitalisation (includes hospitalisation for unstable angina and TIA)    
 
Baseline isk per age using incidence rates in Cowie et al. (1998) (45)   
Relative incidence of CVD 
events (TIA, stroke, angina, 
MI) 
OXVASC cohort study, Rothwell et al. 2005. 91,106 individuals 
presenting with an acute vascular event in Oxfordshire, UK in 2002-5.  
(41) 
3. Adherence to medication   
Probability of adherence to 
treatment with usual care  
 
Estimates from HSE 2011 dataset on adherence to relevant drugs 
(statins, antihypertensives, aspirin) 
Relative risk of adherence: 
polypill versus usual care  
Estimate the probability of adherence to ≥2 antihypertensives, statin 
or anti-platelet for at least four days in the preceding week for 
polypill group versus usual care by applying a binomial regression to 
the UMPIRE dataset.  
4. Treatment effects of medication (antihypertensives, statin, anti-platelet) 
Relative risk of CVD with 
treatment versus no 
treatment  
 
 
 
For base case analysis, conventional meta-analysis of ITT RCT data will 
be used from – 
 Cholesterol Treatment Trialists' Collaboration  
 Blood Pressure Lowering Treatment Trialists' Collaboration  
 Antithrombotic Trialists' Collaboration  
 Law and Wald (46) 
Sensitivity analysis: Test impact of adjusting for adherence within 
trials  
5. Other treatment outcomes (beneficial events and adverse events) and mortality rates  
Adverse Events     
Incident type 2 diabetes Relative risk of diabetes from statins/antihypertensives from meta-
analyses of RCTs  
GI bleeding  Relative risk of bleeding resulting from aspirin using estimates from 
meta-analyses of RCTs 
Cough  Placebo-adjusted relative risk of cough resulting from ACE inhibitors 
using estimate from meta-analyses of RCTs 
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CVD: cardiovascular disease, TIA: transient ischaemic attack, MI: myocardial infarction; ITT: Intention 
to treat, RCT: randomised controlled trial, AHT: antihypertensives, UMPIRE:Use of a Multidrug Pill in 
Reduction in heart failure  Relative risk reduction in heart failure from antihypertensives (33) 
Mortality  
Stroke case fatality (60 day)   
Age <75 
Age > 75+ 
 
Estimate proportion of strokes that are fatal (with risks increasing 
with age).  Estimate using the BHF Compendium of health statistics 
2012, which has data from a record linkage study for England 2010.  
MI case fatality (30 day)   
Age 30-54 Proportion of MI’s that are fatal.  Estimate using Oxford Record 
Linkage pill study. (47) National population based study, including all 
individuals admitted to hospital or who died suddenly from acute MI 
in 2010.  Age was strongest predictive factor for 30-day case fatality. 
Age 55-64 
Age 65-74 
Age 75-84 
Age 85+ 
Death from other causes Estimated from national life tables (Office for National Statistics, 
England)(42) 
6. Costs (medication, monitoring costs, health events)  
Drug costs (£ per year)  
National Health Service (NHS) Electronic Drug Tariff (44) 
 
 
Assumed to be aggregate cost of each drug in the combined pill  
Statins 
AHT drugs 
Aspirin 
Polypill 
Yearly monitoring costs while on medication   
Primary care nurse (£ 
per hour) 
Use NICE Quality Outcomes Framework to identify recommended 
management while on treatment (statins, antihypertensives, 
antiplatelet).  A cost for stopping medication will also be applied (e.g. 
2 GP visits, tests as recommended in NICE clinical guidelines 181) (1) 
 
Costs sourced from Personal Social Services Research Unit Costs and 
NICE clinical guidelines 181  
GP cost (£ per hour) 
Lipid test (£) 
Liver transaminase test 
Blood tests 
Costs of health states and adverse events  
Stroke  Luengo-Fernandez et al. 2012  (48)  
                 “ 
NICE lipids guideline 181 (1) 
                 “ 
                 “ 
                 “ 
                 “ 
NICE Hypertension guidelines 127 (43) 
TIA  
MI  
Angina 
PAD 
Diabetes   
GI bleeding  
Cough (from ACE 
inhibitor use) 
7. Health Related Quality of life  
Stroke  Derived from Health Survey from England (HSE) dataset  
TIA  
MI  
Angina 
PAD 
GI bleeding  
Diabetes  
Cough 
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Reducing Cardiovascular Events, NICE: National Institute for Health and Care Excellence, GP:general 
practitioner  
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Analysis 
The simulation model will run for a sufficient number of iterations to provide stable results.  
Uncertainty in the model parameters will be examined using a probabilistic sensitivity analysis (PSA) 
which will reflect uncertainty over the values of the model inputs.  Non-parametric bootstrapping of 
HSE data will be carried out to examine the uncertainty related to the sampling.  For each PSA 
iteration, one non-parametric bootstrap sample will be drawn from the HSE dataset (by random 
sample with replacement of individuals in the dataset).  An incremental analysis will be conducted 
and incremental cost-effectiveness ratios (ICERs) and net benefit statistics will be estimated.    We 
will also carry out a number of sensitivity analyses to test the impact of varying uncertain 
parameters in the model.   This will include an analysis testing the impact of varying the polypill cost.     
Validation  
The model will be internally and externally validated. A checklist produced by the RUPEE steering 
group based on current published guidelines for checking models will be used, to ensure the 
programmed model behaves as expected according to the theoretical model. (21, 49)  The checklist 
includes tips for model developers, for example on the use of sensitivity analyses to test that the 
model is operating correctly, and re-programming complicated sections of code in another language. 
The model will also be reviewed and tested by an experienced modeller.  The model results will be 
compared with real-world observations or the results of other models. 
Dissemination of results  
The findings of the economic evaluation will be presented to scientific and health care policy 
audiences in open access journals and at national and international conferences.  We will also 
present findings to NHS policy makers and pharmaceutical companies.  
DISCUSSION 
Medication adherence is important for disease management, and benefits of increased adherence to 
preventative medication for CVD include improved clinical outcomes. (5)  The UMPIRE clinical trial 
was conducted to evaluate the effect of a polypill strategy compared to usual care on adherence.  It 
showed that the polypill strategy significantly augmented adherence and this was reflected by 
improvements in SBP and LDL-C. (8)  Whether or not this impact remains in the long term cannot be 
determined from the trial data alone.  The RUPEE (NHS) study is being conducted to evaluate the 
long term impact of a polypill strategy; in particular, the analysis will evaluate the long term impact 
of increased adherence on outcomes.   An economic model is being developed to estimate the long 
term costs and QALYs associated with implementing a polypill strategy in the NHS compared to usual 
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care.   This analysis will represent the first comprehensive cost effectiveness analysis using directly 
applicable clinical trial data.   
 
This paper outlines the process behind the design of the economic model.   We carried out a review 
of published CVD models to identify a modelling approach that would suit the health care decision: 
use of a polypill versus usual care in a population with or at high risk of CVD.   We identified an 
individual simulation model as the most appropriate approach as it allows the heterogeneity in the 
population to be adequately reflected.   The model will use validated disease risk algorithms to 
estimate the probability of an individual experiencing a CVD event or the onset of diabetes.  
Individuals can also experience an increased risk of an adverse event (diabetes, cough and 
gastrointestinal bleeding) from treatment.   The risk of a CVD event will be reduced if the individual 
is adherent to treatment.  We will simulate adherence to treatment using data from the HSE 2011 
dataset.  The probability of adherence in the polypill scenario will be further modified by the relative 
risks of adherence to medication which will be sourced from the UMPIRE trial data for the English 
population.  Costs and QALYs will be estimated for each individual and aggregated across the sample 
population (based on the HSE 2011 dataset).  
 
The RUPEE (NHS) model will have a number of advantages over existing models constructed to 
evaluate a CVD polypill. (50-52) One advantage is the use of an individual simulation model which 
will allow us to capture the heterogeneity in the variation in CVD risk in the UK population unlike 
other models which use Markov type transition state models.  Another is that we will extrapolate 
data on adherence to medication from a nationally representative population dataset (Health Survey 
for England) which will allow us to simulate adherence per individual rather than assuming a 
constant adherence across our population.  We will also allow for adverse events from treatment 
and treatment cessation, therefore more accurately reflecting clinical practice.   
 
It would be preferable to use per protocol treatment effectiveness data in our analysis as intention-
to-treat data already accounts for adherence (people switching and ceasing medication during the 
trial period).  However, per protocol data is difficult to obtain for all drugs, therefore we will use the 
ITT treatment effect data and carry out sensitivity analyses to test the impact.  
 
The introduction of a CVD preventive polypill strategy will simplify pill taking for patients potentially 
leading to greater adherence and better health outcomes.  This analysis will provide information on 
the cost-effectiveness of the polypill in a NHS setting.  
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Figure 1 Flowchart of literature review search for cardiovascular disease models  
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Figure 2 RUPEE (NHS) Simulation model flowchart  
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Abstract  
 
Introduction: The ‘Use of a Multi-drug Pill in Reducing cardiovascular Events’ (UMPIRE) trial 
was a randomised controlled clinical trial evaluating the impact of a polypill strategy on 
adherence to indicated medication in a population with established cardiovascular disease 
of or at high risk thereof. The aim of RUPEE-NHS is to estimate the potential health 
economic impact of a polypill strategy for CVD prevention within the NHS using UMPIRE trial 
and other relevant data.  This paper describes the design of a modelled economic evaluation 
of the impact of increased adherence to the polypill versus usual care amongst the UK 
UMPIRE participants.   
 
Methods and Analysis: As recommended by ISPOR-SMDM modelling guidelines a review of 
published CVD models was undertaken to identify the most appropriate modelling approach 
and structure.  The review was carried out in the electronic databases, MEDLINE and 
EMBASE. 40 CVD models were identified from 57 studies, the majority of economic models 
were health state transition cohort models and individual level simulation models. The 
findings were discussed with clinical experts to confirm the approach and structure. An 
individual simulation approach was identified as the most suitable method to capture the 
heterogeneity in population CVD risk.  RUPEE-NHS will use UMPIRE trial data on adherence 
to medication if receiving the polypill versus usual care to estimate the long term cost-
effectiveness of the polypill strategy.  
 
Dissemination: The evaluation findings will be presented in open access scientific and 
healthcare policy journals and at national and international conferences.  We will also 
present findings to NHS policy makers and pharmaceutical companies.   
 
 
 
Strengths and Limitations 
This paper provides a clear outline of how a model for an economic evaluation is developed. 
 
Providing an outline of the model structure which includes details on the underlying 
epidemiology and data inputs will add transparency to the findings of the RUPEE-NHS study  
 
Though the model has been designed to include all major adverse and beneficial effects of 
treatment, the model structure will not include every potential treatment effect, for 
example the benefits of treatment on Alzheimer's disease will not be included. 
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INTRODUCTION 
Adherence to recommended preventive medication regimes (1,2) in people at high risk of 
cardiovascular disease (CVD) is low, even in high income countries. (3)  Poor adherence is associated 
with greater deterioration in health status and increased health care costs (4) and studies have 
shown that improved adherence to medication is associated with clinical benefits.(5)  CVD 
preventive medication typically involves several drugs and adherence is inversely proportional to the 
number of prescriptions.   Furthermore, physician inertia and patient resistance present barriers to 
initiating or restarting full recommended therapy. A single pill that includes several indicated drugs 
(a “polypill”), may improve long-term adherence by addressing these issues.  If the polypill is priced 
lower than the price of the pills bought separately, it will also make it more affordable. (6,7)  The 
UMPIRE (Use of a Multidrug Pill in Reducing Cardiovascular events) clinical trial was set up to 
evaluate the polypill in patients with or at high risk of CVD.   
 
The UMPIRE trial randomised 2004 participants with established CVD (prior CVD event such as 
stroke or myocardial infarction) or at high risk of CVD (defined as a 5 year risk of >15%) based in 
India, England, Ireland and The Netherlands to either the polypill or usual care.  The primary 
outcome of the trial was adherence to indicated treatments (statin, aspirin and two blood pressure 
lowering drugs), measured as self-reported current use of antiplatelet, statin and ≥2 blood 
pressure lowering therapies for at least 4 days in the week preceding visits (baseline and 
end of trial visits).  Other outcomes included systolic blood pressure (SBP) and low-density 
lipoprotein cholesterol (LDL-C). The trial found that the use of a polypill strategy resulted in greater 
adherence to treatment at 15 months and significant improvements in SBP and LDL-C.  Detailed 
results and a description of the UMPIRE trial protocol are available. (8, 9)  
 
UMPIRE collected data on resource use and self-reported health related quality of life using the EQ-
5D.  In order to estimate the long term costs and health outcomes associated with the polypill 
strategy an economic model is required.   Due to differences in the patient population, care pathway 
and health care costs, separate analyses are needed for the four participating countries.   
 
The analysis of the UMPIRE English trial data, (Researching the UMPIRE Processes for Economic 
Evaluation in the National Health Service (RUPEE-NHS)), aims to estimate the cost-effectiveness of 
the polypill strategy compared to conventional multi-drug therapy for the prevention of established 
cardiovascular disease in English NHS patients with or at high risk of CVD.  The RUPEE (NHS) study 
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will use UMPIRE English trial data on adherence to the polypill and will develop an economic model 
to estimate cost effectiveness.  
 
The aim of this paper is to detail the modelling plan for the RUPEE (NHS) study.    
METHODS 
Model design process  
An economic model has been described as a mathematical framework that represents reality at an 
adequate level of detail to inform clinical or policy decisions. (10)  Guidelines on modelling produced 
by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the 
Society for Medical Decision Making (SMDM) joint taskforce recommend that it is best practice to 
carry out a conceptualisation process prior to programming the economic model.  This process has 
two distinct components: specification of the study question and economic model. (11)   
Specification of the study question 
The first component informs choices about how to structure the economic model and parameters.    
The RUPEE (NHS) study aims to evaluate two different treatment strategies in a population with or 
at high risk of CVD.   The population for the economic model is defined by the inclusion criteria of 
the UMPIRE trial.  (9)  The inclusion criteria are listed below: 
 
• Aged ≥18 years and 
• High CVD risk defined as either established atherothrombotic CVD (history of coronary heart 
disease (CHD), ischaemic cerebrovascular disease, or peripheral arterial disease (PAD)) or a 5 
year risk of ≥15% calculated using the Framingham risk equation  
 
The economic model will evaluate the polypill strategy compared to usual medication. In the 
UMPIRE trial, participants assigned to the polypill received one of 2 versions: version 1 contained 
aspirin 75mg, simvastatin 40mg, lisinopril 10mg and atenolol 50mg, and version 2 contained the 
same ingredients but substituted hydrochlorothiazide 12.5mg for atenolol 50mg.  Participants 
assigned to usual care continued taking medications as prescribed by their general practitioner (GP).   
 
The RUPEE (NHS) study will follow guidelines for modelling health technologies as recommended by 
the National Institute for Health and Care Excellence. (NICE) (1112) Therefore a NHS and Personal 
Social Services (PSS) perspective will be adopted to measure health service resource use and health 
related quality of life will be measured by quality adjusted life years (QALYs) obtained using the EQ-
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5D.  As per the NICE guidelines, costs and QALYS will be discounted at a rate of 3.5% per year.  (12) 
The time horizon reflected in the economic model will be lifetime to represent the chronic nature of 
CVD.  
Conceptualisation of the economic model 
The second component of the conceptualisation process involves defining the economic model.  
There are two steps to this approach.  The first step is to identify the appropriate modelling 
approach.  The modelling approach defines the analytical framework of the economic model.  
Different types of analytical frameworks have been used to represent CVD including decision trees, 
state transition models, compartmental models, individual simulation models and hybrid models 
which often combine elements from different frameworks.  (13-17) 
 
The second step determines the underlying structure of the analytical framework, which will 
represent the disease and care pathway.  The modelling approach needs to reflect: 1) CVD disease 
and care pathway for this population; 2) the beneficial and adverse effect of treatment (polypill or 
usual care); 3) the impact of increased adherence to treatment on health outcomes.   
 
The gGuidelines produced by ISPOR-SMDM on modelling recommend that existing models 
addressing related problems should be reviewed as this approach can help identify both the 
modelling approach and underlying structure.(11) To inform the RUPEE (NHS) economic model, we 
carried out a review of published models evaluating interventions for CVD.   
 
Review of published CVD economic models  
The purpose of the literature review was to identify the appropriate analytical framework to 
represent the decision problem.  The literature review also aimed to inform the underlying model 
structure: disease and care pathway.  
Search strategy 
The search strategy was conducted using the NHS Economic Evaluation Database (NHS EED), the 
NIHR Health Technology Assessment (HTA) monograph series and the NICE guidelines website.  The 
search terms used included ‘cardiovascular disease’, ‘coronary heart disease’, ‘stroke’, ‘myocardial 
infarction’, ‘angina’ and ‘peripheral artery disease’.  Studies were excluded from the review if they 
did not discuss the development or review of an economic model; if no disease states for 
cardiovascular disease were included in the model;  if the focus of the study was a diagnostic test or 
surgical intervention where the economic model used a time frame of <10 years.  Studies were not 
excluded on the basis of intervention (drug treatment or lifestyle intervention) or on the basis of 
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date published or language.   We developed a data extraction form which included fields on model 
purpose, structure, health states and events, transparency and validation.   We did not collate 
information about the findings of the model as the objective of the review was to identify alternative 
model frameworks and methods used to represent CVD.  
 
An initial general literature search identified a 2006 systematic review of CHD policy models by Unal 
et al. which was updated in 2008 by Capewell et al. and expanded to include stroke models. (17,18)  
The review by Capewell et al. identified seven ‘notable’ CHD models (of which six had been 
identified in the previous review by Unal et al.), nine stroke models and several models that were 
currently in development at the time of publication.  We reviewed the notable models and models in 
development identified by Capewell et al.   Citation searching of both systematic reviews was carried 
out to identify other models published since 2008. 
Review findings 
Overall 22 57 studies were identified which reported on 40 CVD models.  Figure 1 presents the 
flowchart for the search strategy.   
The searches found several studies which reported on the same model, for example the IMPACT 
CHD model developed by Capewell et al. was used in analyses of CVD in other populations. (19)  In 
some cases, a model was adapted for different analyses, such as the Sheffield model which was 
developed to evaluate statin therapy and was then adapted for use in the development of the NICE 
guidelines for lipid modification. (1,20) The Sheffield model was also partially used in a whole 
population modelling study by Barton et al. (13)    
Further details on the review can be found in the supplementary appendix.  The appendix includes a 
list of the reviewed models (see Table 1 supplementary appendix), an example of the data extraction 
form and an example of a schematicn illustration and details of one of the reviewed models (see 
Figure 1 supplementary appendix).  Schematic illustrations of several models were used in 
discussions with clinical experts about the different types of modelling approaches. 
 
[Figure 1- Flowchart for search strategy for CVD modelsearch strategy] 
Modelling approach  
The search identified that the two most commonly used modelling approaches were health state 
transition cohort models and individual-level simulation models.  Both approaches were critically 
assessed to determine their suitability to capture the disease and care pathway.  
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A cohort model can be defined as any model which estimates the outcomes for a group of patients, 
whereas with a patient level simulation, outcomes are evaluated at the individual level.  Therefore, 
one of the main differences between the two approaches is how they estimate costs and QALYs: 
cohort models estimate expected costs and QALYs for the modelled population as a whole, whereas 
individual level simulation models estimate cost and QALYs for each individual and the average is 
taken across the sample.  
 
With a health state transition cohort model, the population progresses through a set of mutually 
exclusive health states at regular intervals called cycles, determined by a predefined transition 
matrix.  Health state transition cohort models are also commonly called Markov models.  However, 
such models are only Markovian when they display the Markovian ‘memoryless’ property where the 
progression of the patient through the model is only dependent on the current state in which the 
patient resides and not on anything that happened before they entered that health state.   It is also 
possible to model at the individual level using a state transition model by sampling probabilities for 
each individual patient to experience a particular transition in each model cycle. (21) 
 
Both model approaches can use a discrete time approach: with this approach the model cycle length 
will be defined in advance.  The cohort or individual progress through health states or events which 
represent the disease pathway and only one event may occur within each cycle length.  Costs and 
QALYs are updated once per cycle.  Alternatively, individual level simulation models are often set up 
as discrete event simulations (DES).  With a DES approach, an event can occur at any time point, for 
example, an event could occur at three months, one year and twenty years.  As an event occurs, 
costs and QALYs are recorded and updated for each individual.  
 
A health state transition model was used to develop NICE guidance for lipid modification treatment. 
(1) The limitation of this approach is that it may be unable to capture the underlying heterogeneity 
in the population.  Individual CVD risk can be estimated using CVD risk algorithms such as QRISK2 
which use a range of patient characteristics such as age, sex, ethnicity, systolic blood pressure and 
body mass index to estimate a 10 year CVD risk.(22)  To capture this complexity in a health state 
transition model would require the construction of a large number of subgroups to reflect different 
subsets of patient characteristics and the variation in CVD risk in the population.  This could become 
impractical to model.  It also has the disadvantage that accuracy could be lost by using 
representative values for subgroups.  An individual simulation model structure may be more 
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appropriate to model the level of detail required to estimate CVD outcomes reflective of those in the 
population.   
 
The Markovian memoryless property means that data on individual patients’ history is not 
retained as they progress through the model.  Accounting for individual patient history in a 
Markov model would require multiplying the number of health states to an infeasible level 
where the model would become too complex and impracticable to run. 
 
To accurately identify the effectiveness of each treatment strategy in a population with or at high 
risk of CVD, an individual simulation model was deemed the most appropriate for the RUPEE (NHS) 
study to reflect the heterogeneity in the population which impacts on the risk of a CVD event and 
subsequent costs and outcomes.  The individual simulation model will use a discrete event approach 
to handle time.(21) 
Model structure  
The findings of the review were discussed with clinical experts to confirm the health events and the 
methods used to model the progression of persons through the disease pathway.   
Model events (CVD, diabetes and adverse events) 
The most commonly included types of CVD events in the reviewed models were CHD (angina and 
myocardial infarction), cerebrovascular events (transient ischaemic attack (TIA) and stroke) and 
pPeripheral arterial disease (PAD).  It was decided that the CVD events relevant for the current 
model would reflect those most commonly included in prior such models.  PAD will not be included 
as a CVD event in the model as there is less likely to be a definable acute PAD event compared to 
other CVD events such as MI and stroke.  We will assume that patients can experience more than 
one CVD event in their lifetime.  The risk of CVD will also be assumed to change with age in the 
model.   
 
Diabetes is a risk factor for CVD with a substantial cost and impact on health related quality of life, 
therefore diabetes will be included as a comorbidity in the model.   The risk of new onset diabetes 
will be estimated using the QDiabetes risk algorithm.(23)   
 
Adverse effects from treatment will include an increase in the risk of new onset diabetes resulting 
from treatment with statins and antihypertensive drugs.  (24-27)  The risk of a persistent cough 
resulting from treatment with angiotensin-converting-enzyme inhibitors (ACE inhibitors) will be 
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included as an event.  The probability of a cough resulting from treatment will be sourced from 
meta-analyses of randomised controlled trial (RCT) data for ACE inhibitors. As aspirin use is 
associated with an increased risk of gastrointestinal bleeding,(28,29) an increased risk of 
gastrointestinal bleeding from treatment with aspirin will be included.  
 
Renal impairment will not be included in the model as an adverse effect of ACE inhibitors. Whilst 
ACE inhibitors may cause an acute rise in serum creatinine in a few patients with renal artery 
stenosis and more generally cause a slight short term increase in creatinine levels, the effects are 
complex and there may be a net improvement in renal function overall in a treated population.  The 
rate of falls and fractures will be estimated not to alter, given the evidence from randomised trials of 
blood pressure lowering agents, although this is an area of debate with regard to patients with 
higher levels of frailty.  (30, 31)    
 
Other adverse effects from statin treatment such as liver dysfunction and myopathy will not be 
included in the model as these cases are rare and are assumed to have a minimal impact on 
outcomes. (1) (32)   
 
Treatment with antihypertensives is associated with a reduction in heart failure, therefore this will 
be included as an outcome in the model. (33)   Other outcomes of treatment are likely but will not 
be included – for example a reduction in cancer with aspirin use of more than 5 years. (34)   
 
Progression of individuals through model   
The progression of persons through the disease pathway differs depending on the modelling 
approach: health state transition models such as the Markov model developed for NICE guidelines 
on lipid modification use a predefined transition matrix to determine progression through the CVD 
health states.(35) Alternatively, simulation models can use risk algorithms to estimate the 
probability of CVD events or new onset diabetes.  The NICE guidelines for lipid modification 
recommend the use of QRISK2, which is a risk algorithm derived to estimate primary CVD risk in UK 
populations. (1,22)  The QRISK2  risk algorithm predicts the risk of a 10 year CHD event (angina, MI) 
or a cerebrovascular event (TIA, stroke).  It does not include the risk of PAD.  An alternative CVD risk 
algorithm is the Framingham equation;(36), however, a validation study comparing QRISK2 and 
Framingham found that QRISK2 is better calibrated to a UK population.(37)  The RUPEE (NHS) model 
will therefore use the QRISK2 risk algorithm. 
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RUPEE (NHS) economic model  
Figure 2 depicts the flowchart of the RUPEE (NHS) model structure.  The oval shapes represent data 
inputs to the model, whereas the rectangular shapes represent processes.  
 
[Figure 2 - Flowchart of RUPEE (NHS) model structure] 
Model description  
In the RUPEE (NHS) model costs and QALYs are recorded for each individual and an average cost and 
QALY for the simulated population are estimated.  The RUPEE (NHS) model will be run twice, once to 
simulate costs and QALYs under usual care and once to simulate costs and QALYs under the polypill 
strategy scenario (polypill scenario will include polypill version 1 and version 2).  Individuals 
representing the UMPIRE trial inclusion criteria will enter the model (label 1 in Figure 2), and their 
baseline risk of a CVD n event and onset diabetes will be estimated using the QRISK2 CVD risk 
algorithm and or the QDiabetes algorithm (label 2 in Figure 2) respectively.  For each individual, 
whether or not they are adherent to medication will be simulated using Monte Carlo simulation 
based on the probability of adherence in usual care (label 3a in Figure 2).  If the individual is 
simulated to be adherent to medication their risk of a CVD event will be modified by a treatment 
effect (label 4 in Figure 2).  In the polypill scenario ofin the model, the probability of adherence will 
be further modified by the relative risk of adherence to medication.   For simulated adherent 
individuals taking the polypill, the risk of an event will be further modified by the relative risk of 
adherence for polypill versus usual care.  The relative risk of adherence for polypillto medication 
versus usual care will be sourced from the UMPIRE trial data (label 3b in Figure 2).  Individuals may 
experience a CVD event or onset of diabetes based on their estimated CVD and diabetes risk, which 
will be estimated using the QRISK2 and QDiabetes algorithms.   Individuals may also experience an 
adverse reaction to medication (if adherent) including gastrointestinal bleeding, early onset of 
diabetes and a persistent cough.  Costs and QALYs will be recorded for each event (including adverse 
events).   Individuals can experience more than one event (model run for lifetime horizon) and 
patient characteristics such as age and history of previous events, such as a stroke or new onset 
diabetes, are updated during the model run, with an ensuing reflective increase in the risk of an 
event.  
Input parameters  
Each point in the flowchart is labelled and a description of the process or data requirement label is 
described below.  Table 1 provides further details on data input parameters for the RUPEE-NHS 
model and potential sources of data. 
 
1. Population Dataset   
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We will use the 2011 Health Survey for England (HSE) as a population dataset for the economic 
model.  The HSE is a cross sectional survey which contains anonymised information on a 
representative sample of the population.  The 2011 HSE dataset collected information on CVD, 
including individual CVD events and medication history. The dataset also contains information on 
demographic and socio-economic characteristics and health related data such as body mass index 
(BMI), SBP and LDL-C and history of CVD events.  These data are required in order to estimate 
individual baseline risks of CVD and diabetes in the model.   
 
2. Calculation of baseline risks of events without treatment 
Baseline risks for CVD for each sampled individual will be calculated using published risk algorithms.  
As per recent NICE guidance for lipid modification, we will use the recommended algorithm for CVD 
risk, QRISK2.  (1,221)   The algorithm was derived using QRESEARCH, a large database derived from 
the pseudonymised health records of over 13 million patients registered with a general practitioner 
in the UK.  If an individual has established CVD (previously experienced a CVD event), we will 
estimate a secondary CVD risk using the REACH algorithm. (38) A baseline risk for the onset of 
diabetes will be estimated using the QDiabetes algorithm. (23)   
 
 
3a. Simulating adherence to treatment under usual care  
The RUPEE study will evaluate the effect of adherence to medication on long term costs and health 
outcomes measured using quality adjusted life years (QALYS).  The average rates of adherence in 
clinical trials can be higher than in actual practice (4) as seen in the UMPIRE clinical trial population 
which had an atypically high baseline adherence rate.  Instead, adherence rates to medication 
(antihypertensives (AHT), statins and aspirin) under a usual care setting will be sourced from the 
2011 HSE dataset.  Participants in the 2011 HSE self-reported all the prescribed medications they 
had taken in the last 7 days.  This was coded in the HSE dataset using the British National Formulary 
(BNF) classifications codes.  Using this data, we are able to identify the medication patients were 
prescribed and identify whether or not they were taking the prescribed medication in the last week.  
This will reflect adherence to medication in a usual care population.  The data will be used to 
estimate the probability of each person being adherent or not to medication.  Individual 
characteristics will be used as predictors of adherence: the characteristics will be chosen by referring 
to studies which have assessed predictors of adherence in persons taking treatment for CVD.  (39, 
40) A generalized linear mixed regression model will be used to estimate the probability of 
adherence to medication for each individual.  The probability of persistence with medication will not 
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be assumed to be constant, and the model will include a probability of ceasing medication over time.  
The probability of medication cessation will be sourced from published literature on adherence.  
 
3b. Estimate relative risks of adherence to medication for polypill versus usual care   
We will estimate the relative risks of adherence to medicationfor the polypill strategy versus usual 
care, using a generalised linear mixed regression model which will be applied to the UMPIRE trial 
dataset (UK dataset).   A generalised linear mixed regression model will be applied to the UMPIRE 
trial dataset, with adherence to medication indicated as taking ≥ 2 antihypertensive drugs, a statin 
and aspirin for at least four days in the week prior to a recorded visit.  The This definition of 
adherence reflects that used in UMPIRE. (8).  In the polypill scenario in the model, the probability of 
being adherent to medication will be further modified by the relative risks.  
 
4. Adjust risk of events for treatment  
We will source data on the treatment effects of statins, antihypertensives and aspirin from meta-
analyses of intention-to-treat RCTs.  Intention-to-treat analyses account for non-adherence in their 
findings, and therefore underestimate the impact of treatment on event risk.  To overcome this, we 
will carry out sensitivity analyses to test the impact of adjusting for adherence within the trial.   The 
risk of a CVD event will be adjusted by the relative risk of treatmenttreatment with statins, 
antihypertensives and aspirin,, based on the treatment medication(s) the person is taking and 
whether or not they are adherent to medication. 
 
5. Simulation of events 
Individuals in the model can experience a CVD event at a rate governed by their calculated baseline 
risk (estimated by the QRISK2 or REACH algorithms) and adjusted for treatment effects if they have 
been simulated as adherent to treatment.  CVD events will be categorised as a TIA, stroke, MI or 
angina.  The relative incidence of each CVD event will be determined using published incidence 
data.(3941)  Similarly, the risk of new onset diabetes will be calculated using the QDiabetes 
algorithm.  We will simulate the incidence of adverse events as a result of treatment: new onset 
diabetes and gastrointestinal bleeds.   Data on the probability of an adverse event will be sourced 
from meta-analyses of randomised controlled trials for the relevant drugs.  Mortality risk will be 
modelled as mortality from stroke and MI and other cause mortality.  Data on other cause mortality 
will be estimated using national life tables for England and Wales. (4042) 
 
6. Assign cost and quality of life values 
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Costs and QALYs associated with each individual’s simulated lifetime profile of CVD and related care 
will be estimated.  Costs and quality adjusted life years (QALYs) will accrue for each person to reflect 
events, such as a stroke or new onset diabetes.  Costs and utility values for health events will be 
sourced from published studies including the NICE guidelines for lipid modification and 
hypertension. (1,35,4143)  Costs of medication will be sourced from the NHS National Drug 
Tariff.(4244) 
 
 
 
 
7. Change in age, treatment, CVD status and type II diabetes status 
The simulation model will run for each individual for lifetime duration (death or maximum age of 
100 years) and patient characteristics will be updated after each event or every 10 years (depending 
on which event occurs first).  A 10 year update is used as the QRISK2 algorithm returns a 10 year CVD 
risk.  
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Table 1) Input parameters  
Model inputs Source   
1. Individual dataset    
Population dataset Initial patient characteristics (see Figure 2) for cohort of patients 
drawn from a representative national sample: Health Survey for 
England (HSE) dataset 2011.  The dataset will include patients who 
meet the entry criteria for the UMPIRE trial. 
2. Calculation of baseline risks   
Risk calculators  
 
 
 
 
 
 
 
 
 
 
 
 
Risk of heart failure 
Risk of first CVD event and onset of type 2 diabetes estimated for 
individuals using QRISK2 and QDiabetes.(23, 24) 
 
QRISK2:  10 year CVD risk (CVD outcomes defined as angina, MI, TIA 
and stroke) 
QDiabetes: risk of acquiring type 2 diabetes over 10 year time period 
 
Risks for subsequent CVD events estimated for individuals using the 
REACH algorithm.  (38) 
CVD outcomes defined as cardiovascular death (includes fatal stroke 
and MI), non-fatal MI, non-fatal stroke, and cardiovascular 
hospitalisation (includes hospitalisation for unstable angina and TIA)    
 
Baseline risk per age using incidence rates in Cowie et al. (1998) 
(4345)   
Relative incidence of CVD 
events (TIA, stroke, angina, 
MI) 
OXVASC cohort study, Rothwell et al. 2005. 91,106 individuals 
presenting with an acute vascular event in Oxfordshire, UK in 2002-5.  
(3441) 
3. Adherence to medication   
Probability of adherence to 
treatment with usual care  
 
Estimates from HSE 2011 dataset on adherence to relevant drugs 
(statins, antihypertensivesAHT, aspirin) 
Relative risk of adherence: 
polypill versus usual care  
Estimate the probability of adherence to ≥2 antihypertensivesAHT, 
statin or anti-platelet for at least four days in the preceding week  for 
polypill group versus usual care by applying a binomial regression to 
the UMPIRE dataset.  
4. Treatment effects of medication (antihypertensivesAHT, statin, anti-platelet) 
Relative risk of CVD with 
treatment versus no 
treatment  
 
 
 
For base case analysis, conventional meta-analysis of ITT RCT data will 
be used from – 
 Cholesterol Treatment Trialists' Collaboration  
 Blood Pressure Lowering Treatment Trialists' Collaboration  
 Antithrombotic Trialists' Collaboration  
 Law and Wald (4446) 
Sensitivity analysis: Test impact of adjusting for adherence within 
trials  
5. Other treatment outcomes (beneficial events and adverse events) and mortality rates  
Adverse Events     
Incident type 2 diabetes Relative risk of diabetes from statins/antihypertensives from meta-
analyses of RCTs  
GI bleeding  Relative risk of bleeding resulting from aspirin using estimates from 
meta-analyses of RCTs 
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Cough  Placebo-adjusted relative risk of cough resulting from ACE inhibitors 
using estimate from meta-analyses of RCTs 
Reduction in heart failure  Relative risk reduction in heart failure from antihypertensives (33) 
Mortality  
Stroke case fatality (60 day)   
Age <75 
Age > 75+ 
 
Estimate proportion of strokes that are fatal (with risks increasing 
with age).  Estimate using the BHF Compendium of health statistics 
2012, which has data from a record linkage study for England 2010.  
MI case fatality (30 day)   
Age 30-54 Proportion of MI’s that are fatal.  Estimate using Oxford Record 
Linkage pill study.(study. (4547) National population based study, 
including all individuals admitted to hospital or who died suddenly 
from acute MI in 2010.  Age was strongest predictive factor for 30-day 
case fatality. 
Age 55-64 
Age 65-74 
Age 75-84 
Age 85+ 
Death from other causes Estimated from national life tables (Office for National Statistics, 
England)(4042) 
6. Costs (medication, monitoring costs, health events)  
Drug costs (£ per year)  
National Health Service (NHS) Electronic Drug Tariff (44) 
 
 
Assumed to be aggregate cost of each drug in the combined pill  
Statins 
AHT drugs 
Aspirin 
Polypill 
Yearly monitoring costs while on medication   
Primary care nurse (£ 
per hour) 
Use NICE Quality Outcomes Framework to identify recommended 
management while on treatment (statins, antihypertensivesAHT, 
antiplatelet).  A cost for stopping medication will also be applied (e.g. 
2 GP visits, tests as recommended in NICE clinical guidelines 181) (1) 
 
Costs sourced from Personal Social Services Research Unit Costs and 
NICE clinical guidelines 181  
GP cost (£ per hour) 
Lipid test (£) 
Liver transaminase test 
Blood tests 
Costs of health states and adverse events  
Stroke  Luengo-Fernandez et al. 2012  (4648)  
                 “ 
NICE lipids guideline 181 (1) 
                 “ 
                 “ 
                 “ 
                 “ 
NICE lipids Hypertension guidelines 127 (43) 
TIA  
MI  
Angina 
PAD 
Diabetes   
GI bleeding  
Cough (from ACE 
inhibitor use) 
7. Health Related Quality of life  
Stroke  Derived from Health Survey from England (HSE) dataset  
TIA  
MI  
Angina 
PAD 
GI bleeding  
Diabetes  
Cough 
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CVD: cardiovascular disease, TIA: transient ischaemic attack, MI: myocardial infarction; ITT: Intention 
to treat, RCT: rRandomised controlled trial, AHT: antihypertensives, UMPIRE:Use of a Multidrug Pill in 
Reducing Cardiovascular Events, NICE: National Institute for Health and Care Excellence, GP:general 
practitioner  
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Analysis 
The simulation model will run for a sufficient number of iterations to provide stable results.  
Uncertainty in the model parameters will be examined using a probabilistic sensitivity analysis (PSA) 
which will reflect uncertainty over the values of the model inputs.  Non-parametric bootstrapping of 
HSE data will be carried out to examine the uncertainty related to the sampling.  For each PSA 
iteration, one non-parametric bootstrap sample will be drawn from the HSE dataset (by random 
sample with replacement of individuals in the dataset).  An incremental analysis will be conducted 
and incremental cost-effectiveness ratios (ICERs) and net benefit statistics will be estimated.    We 
will also carry out a number of sensitivity analyses to test the impact of varying uncertain 
parameters in the model.   This will include an analysis testing the impact of varying the polypill cost.     
Validation  
The model will be internally and externally validated. A checklist produced by the RUPEE steering 
group based on current published guidelines for checking models will be used, to ensure the 
programmed model behaves as expected according to the theoretical model. (21, 4497)  The 
checklist includes tips for model developers, for example on the use of sensitivity analyses to test 
that the model is operating correctly, and re-programming complicated sections of code in another 
language. The model will also be reviewed and tested by an experienced modeller.  The model 
results will be compared with real-world observations or the results of other models. 
Dissemination of results  
The findings of the economic evaluation will be presented to scientific and health care policy 
audiences in open access journals and at national and international conferences.  We will also 
present findings to NHS policy makers and pharmaceutical companies.  
DISCUSSION 
Medication adherence is important for disease management, and benefits of increased adherence to 
preventative medication for CVD include improved clinical outcomes. (5)  The UMPIRE clinical trial 
was conducted to evaluate the effect of a polypill strategy compared to usual care on adherence.  It 
showed that the polypill strategy significantly augmented adherence and this was reflected by 
improvements in SBP and LDL-C. (8)  Whether or not this impact remains in the long term cannot be 
determined from the trial data alone.  The RUPEE (NHS) study is being conducted to evaluate the 
long term impact of a polypill strategy; in particular, the analysis will evaluate the long term impact 
of increased adherence on outcomes.   An economic model is being developed to estimate the long 
term costs and QALYs associated with implementing a polypill strategy in the NHS compared to usual 
Page 43 of 66
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
19 
 
care.   This analysis will represent the first comprehensive cost effectiveness analysis using directly 
applicable clinical trial data.   
 
This paper outlines the process behind the design of the economic model.   We carried out a review 
of published CVD models to identify a modelling approach that would suit the health care decision: 
use of a polypill versus usual care in a population with or at high risk of CVD.   We identified an 
individual simulation model as the most appropriate approach as it allows the heterogeneity in the 
population to be adequately reflected.   The model will use validated disease risk algorithms to 
estimate the probability of an individual experiencing a CVD event or the onset of diabetes.  
Individuals can also experience an increased risk of an adverse event (diabetes, cough and 
gastrointestinal bleeding) from treatment.   The risk of a CVD event will be reduced if the individual 
is adherent to treatment.  We will simulate adherence to treatment using data from the HSE 2011 
dataset.  The probability of adherence in the polypill scenario will be further modified by the  with an 
increased modified relative risk reductionprobability of adherence in the polypill scenario if the 
person is adherent to the polypill.  The relative risks of adherence to the polypill versus usual 
caremedication which will be sourced from the UMPIRE trial data for the English population.  Costs 
and QALYs will be estimated for each individual and aggregated across the sample population (based 
on the HSE 2011 dataset).  
 
The RUPEE (NHS) model will have a number of advantages over existing models constructed to 
evaluate a CVD polypill. (4850-5052) One advantage is the use of an individual simulation model 
which will allow us to capture the heterogeneity in the variation in CVD risk in the UK population 
unlike other models which use Markov type transition state models.  Another is that we will 
extrapolate data on adherence to medication from a nationally representative population dataset 
(Health Survey for England) which will allow us to simulate adherence per individual rather than 
assuming a constant adherence across our population.  We will also allow for adverse events from 
treatment and treatment cessation, therefore more accurately reflecting clinical practice.   
 
It would be preferable to use per protocol treatment effectiveness data in our analysis as intention-
to-treat data already accounts for adherence (people switching and ceasing medication during the 
trial period).  However, per protocol data is difficult to obtain for all drugs, therefore we will use the 
ITT treatment effect data and carry out sensitivity analyses to test the impact.  
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The introduction of a CVD preventive polypill strategy will simplify pill taking for patients potentially 
leading to greater adherence and better health outcomes.  This analysis will provide information on 
the cost-effectiveness of the polypill in a NHS setting.  
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Supplementary appendix  
Section 1-  Literature review  
The purpose of the literature review was to identify the appropriate analytical framework to 
represent the decision problem.  The literature review also aimed to inform the underlying model 
structure: disease and care pathway.  
A general search of the literature identified a known review of coronary heart disease policy models 
by Unal et al. (2006).(1) This review was updated and expanded in 2008 by Capewell et al. to include 
stroke models. (2) A search carried out in Medline found no further systematic reviews of coronary 
heart disease or cardiovascular disease models published since 2008.  The review by Capewell et al. 
(2008) identified seven notable CHD models (six of these had been identified in the previous review 
by Unal et al), nine stroke models and several models that were currently in development at the time 
of publication.  The notable models and models in development were reviewed.  Additionally, citation 
searching of both reviews was carried out to potentially identify any further models published since 
2008. 
Development of search strategy  
The purpose of the review was not to identify every single model for cardiovascular disease but rather 
to identify potential model structures that could be adapted or used to help construct the RUPEE NHS 
model.  Initially, it was planned that an updated search using the search strategy devised by Unal et 
al. (2006) and updated by Capewell et al. (2008) would be used.  However, the purpose of both reviews 
had been to identify notable policy models at the population level. It was felt that redoing this review 
could potentially fail to return other models which could be used such as those developed for NICE 
guidelines.  The choice of databases was discussed with a systematic reviewer based at HERG.  The 
search strategy was carried out using the following databases: 
 NHS economic evaluation Database (NHS EED): this database contains economic evaluations 
of healthcare interventions and is produced by the NIHR Centre for Reviews and 
Dissemination (CRD) at the University of York, UK.   
 National Institute for Health Research (NIHR) Health Technology Assessment (HTA) 
monograph series: This series publishes research about the effectiveness, costs and broader 
impact of healthcare treatments and tests (within a UK National Health Service (NHS) setting). 
 National Institute for health and care excellence (NICE) website: this database publishes 
evidence based guidance on preventative, diagnostic and treatment interventions for disease 
and ill health.    
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NHS EED was identified as an appropriate database as this database reviews and produces critical 
commentaries economic evaluations of ‘key’ relevance to the UK NHS.  The critical commentaries 
provide a summary of the overall reliability and generalisability of the study. The NICE HTA monograph 
series publishes research including cost-effectiveness analyses of healthcare treatment and tests; the 
series was searched to identify published HTA’s which have developed or used a cardiovascular 
disease model.  The NICE guidelines website was searched to identify guidelines related to 
cardiovascular disease (for example guidelines for lipid modification).    
The search terms used in the search included ‘cardiovascular disease’, ‘coronary heart disease’, 
‘stroke’, ‘myocardial infarction’, ‘angina’ and ‘peripheral artery disease’.  Appendix 1 contains further 
details of the searches carried out in each database. 
Exclusion criteria 
Studies were excluded if they did not discuss the development or review of an economic model; if no 
disease states for cardiovascular disease were included in the model; if the focus of the study was a 
diagnostic test or surgical intervention where the focus of the evaluation was a short term follow up, 
(<10 years).  Studies were not excluded on the basis of intervention (treatment or lifestyle 
intervention) or on the basis of date published or language.  
Data extraction form 
The use of a standard checklist such as the Drummond economic evaluation checklist was considered 
to review each study but was found to be unsuitable for reviewing the models as the design of the 
checklist leads the reviewer to evaluate the cost-effectiveness analysis inputs and outcomes with only 
two questions referring to the model structure: regarding the choice and details of the model.  (3) 
Therefore, a data extraction form was designed to extract data that was required to meet the purpose 
of the review.  An initial data extraction form was developed which extracted data on the following 
items: 
 Paper (Author, Year) 
 Purpose of the Model 
 Setting and Population 
 Interventions  
 Type of model (Simulation, Markov Model, other) 
 Brief description of Model 
 Cardiovascular disease risk algorithms  
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 Risk factors included to calculate cardiovascular disease risk  
 Disease stages (Health states) included in model  
 Source of data inputs used in model (Population data, mortality rate, treatment uptake and 
effectiveness, other) 
 Probabilistic Distributions and Parameters 
The form was refined further to only extract data which was relevant for this review.  As the purpose 
of the review was to inform the model structure and design the extraction of data inputs and 
probabilistic distributions and parameters were removed from the data extraction form.  The initial 
data extraction form also extracted data on the quality of each model.  An assessment of quality 
criteria for models has been suggested in guidelines from the International Society for 
Pharmaeconomics and Outcomes Research (ISPOR). (4,5) The systematic review by Unal et al. used 
the guidelines suggested by ISPOR to create a grading system for model papers based on the 
sensitivity, validity and transparency of a model.   As the purpose of the review is not to evaluate 
inputs, the form was further refined and information on sensitivity analyses were not extracted.  
However, the data extraction forms did extract information on whether the model had been validated 
(including details of validation).  The refined data extraction form also included a section on whether 
the model had been adapted for further studies.   An example of a completed data extraction form 
can be found in Section 2.  
Categorisation of Models  
Each model was categorised (modelling approach) based on the taxonomy of model structures as 
developed by Brennan et al. (6)  
Findings  
The majority of models identified for review used a state transition approach (13 models) with five 
models adopting a hybrid state transition, in all cases a hybrid Markov-simulation model. (7-24) Only 
one decision tree model was identified, whereas 10 individual simulation model were identified. (25-
35)  Another popular approach was to use a systems dynamics modelling approach (5 models).(36-40)  
Other modelling approaches identified included an age period cohort (APC) approach (1 model); a 
tabular cell based model used by the World Health Organisation to estimate the global burden of 
disease; two life table approaches; a mathematical stroke epidemiological model and the Archimedes 
model which uses a method based on Fourier expansions using standard mathematical techniques to 
simulate individuals (proprietary model). (41-46) 
 
The identified models categorised according to modelling approach can be found in Table 1.    
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The purpose of the review was to identify the best modelling approach for the RUPEE study.  To this 
end, we reviewed the models to identify advantages and disadvantages of each approach.  Details of 
the advantages and disadvantages of the two main modelling approaches used (Markov models and 
Simulation models) can be found in the paper associated with this supplementary appendix.  Table 2 
presents a summary of six models which used a different modelling approach (decision tree, state 
transition model, simulation model, systems dynamic and hybrid model).    
 
Additionally, schematic illustrations of several models were used to aid discussions about the different 
types of modelling approaches with clinical experts.  Figure 1 in Section 2 is an example of the 
schematic illustration for the model developed for the NICE clinical guidelines 181 which evaluated 
statin treatment in primary and secondary care. (47) 
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Table 1- Models identified in Literature Review Search  
Life Table/Cell 
base/Tabular model 
Decision Tree State Transition Hybrid model Simulation  Systems Dynamic/ 
Compartmental model 
WHO Global Burden of 
Disease (42) 
Whitfield et al. 
(UK) (25) 
Grover et al. CVD Life 
Expectancy model (Canada)-
Markov Model (7) 
Rotterdam Ischemic 
disease and stroke (RISC) 
model 
Markov model structure 
with individual simulation 
(20) 
Southampton CHD 
Policy Analysis Model 
‘Treatment’ – 
individual simulation 
(26) 
Weinstein et al. CHD 
heart disease policy 
model (USA)  (36)  
Schau et al. Stroke 
Model (Denmark)(45) 
 Stroke Treatment Economic 
Model (STEM)- USA (8) 
Duke Stroke Policy and 
Prevention Model USA 
(SPPM) 
Semi-Markov/simulation 
model (21) 
CHD Policy Analysis 
Model ‘Prevention’- 
individual simulation 
(27) 
IMPACT model 
(including adaptations 
of model) (37) 
Tobias et al. APC 
Model (41) 
 RIVM Chronic Disease- 
Markov Model (9) 
A Dynamic modelling tool 
for generic health impact 
assessments (Dynamo-
HIA) 
Markov/partial simulation 
model (22) 
Prevent – Macro 
simulation model using 
aggregated data (policy 
tool) (28) 
Sundberg et al.- 
Compartmental model 
(38) 
Struijs et al. Dynamic 
multi-state life table 
(43) 
 Ward et al . (ScHAAR statins 
model) and adaptations- 
Markov Model (10) (47) 
 
 
Korean Individual 
Microsimulation Model for 
Cardiovascular Health 
Interventions 
Hybrid Markov/ individual 
simulation model (23) 
Foresight Obesity 
Model UK – stochastic 
cohort simulation 
approach (29) 
Model of Resource 
Utilization, Costs and 
Outcomes for Stroke, 
(MORUCOS, Australia)- 
Compartmental model 
(39) 
Archimedes (USA) (46)  Smith-Spangler et al-  
Markov Model (11) 
Soresen et al. Simulation 
model 
Markov model/individual 
simulation (24) 
POHEM- Canada, 
Microsimulation (30) 
PopMod: a longitudinal 
population model with 
two interacting disease 
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states- Compartmental 
model (40) 
 
Malik et al. Life Table 
(44)  
 Newman et al. Combination 
polypharmacy, Markov 
model 12) 
 EUROASPIRE III health 
economics project- 
Individual simulation 
(31) 
 
  Grosso et al, Markov Model 
13) 
 OECD and WHO 
microsimulation 
chronic disease 
prevention simulation 
model- 
microsimulation (32) 
 
  Gillespie et al. SPHERE 
Markov Model (14) 
 Ara et al. Obesity 
model- Cohort 
simulation (33) 
 
  Wisloff et al. NorCaD Markov 
Model  (15) 
 Department of Health 
Vascular Checks 
Model- Simulation (34) 
 
  Nash et al.  Markov Model 
(16) 
 Green et al. Chronic 
Disease Policy Model- 
Discrete Event 
Simulation (35) 
 
  Lovibond et al. Markov 
Model (17) 
   
  Greving et al. Markov Model 
(18) 
   
  NICE Clinical Guidelines 
CG127 (19) 
   
WHO- World Health Organisation, APC- Age Period Cohort, CHD- Coronary heart disease, OECD- Organisation for Economic Co-operation and Development, 
ScHAAR- School of Health and Related Research, NICE- National Institute for Health and Care Excellence  
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Table 2- Summary of CVD models  
Model name 
(Author) 
Model Type Risk factors Health States/Events Transparency & Validation Limitations 
Stroke Model 
(Whitfield et al.) 
(25) 
Decision Tree 
BMI, Type II diabetes, 
smoking, total and HDL 
cholesterol, SBP 
Acute episode included: 
Acute CVD, Elective CVD, 
Heart Failure, Renal 
replacement procedures, 
Stroke, Diabetes 
(hypoglycaemia) 
Internal validation: predicted 
number of CVD related 
admissions based on risk 
factor data compared to 
actual data (from five UK 
primary care trusts)- found 
results to be accurate 
 
No external validation 
conducted 
The model uses an 
aggregate approach 
despite having individual 
data 
 
Short time frame also 
used, suitable for decision 
tree but potentially if a 
longer time frame was 
used this would not be a 
suitable model 
NICE lipid 
modification 
guidelines 
economic model 
(CG181) (47) 
Markov Model Not explicitly stated 
Death from 
cardiovascular cause and 
non CVD death, stable 
angina, unstable angina, 
myocardial infarction, 
transient ischaemic 
attack, heart failure, 
peripheral artery disease 
and post event states for 
each non-fatal event  
Yes, the model structure, 
assumptions and inputs are 
clearly reported 
 
Validation has not been 
stated, this is an update of a 
previously widely used model 
(ScHAAR statins model NICE 
TA94) (10) 
The model is limited by the 
Markovian assumption of 
memoryless though it does 
have tunnel (post event) 
states.  The cohort can 
experience each event 
only once 
 
The model structure is not 
suitable to simulate a 
heterogeneous population 
RISC state 
transition hybrid 
model (20) 
Hybrid Markov 
Model 
sex, age, smoking status, 
SBP & DBP, BMI, waist to 
hip ratio, ankle-brachial 
index, levels of plasma 
glucose, total cholesterol, 
Well, Stroke, CHD, CHD & 
Stroke, Other Death, CVD 
death 
Internal validation: 
cumulative incidences 
simulated by RISC model 
compared to Rotterdam study 
incidences- similar. 
Allow for individual 
heterogeneity to be 
modelled, but limited by 
Markovian state transition 
model (progression 
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HLD, creatinine, family 
history CVD, hypertension, 
taking antihypertensives 
or BP over 160/90, 
presence diabetes II, 
intermittent claudication, 
angina, AF, TIA or 
prevalent CVD 
 
External validity tested- used 
NORFOLK EPIC dataset and 
simulation incidences using 
model- incidences similar 
between states and 
handling of time). Could 
potentially be slow 
computationally to run 
(uses six transition 
probabilities equations per 
individual) if more health 
states or risk factors are 
required  
IMPACT (Capewell 
et al) (37) 
Compartmental/ 
systems 
dynamics model 
Cigarette smoking, total 
cholesterol, systolic blood 
pressure, BMI, diabetes, 
physical activity and fruit 
and vegetable 
consumption   
Deaths prevented or 
postponed from 
reductions in risk were 
the main CHD outcome 
 
Nine patient groups were 
evaluated: 
 
Patients treated in 
hospital for acute 
myocardial infarction 
(MI) 
 
Patients admitted to 
hospital with unstable 
angina 
 
Community dwelling 
patients who have 
survived a MI >1yr 
 
Patients who had 
undergone a previous 
A technical appendix was 
provided a recent paper which 
used the IMPACT model and 
this provided detailed 
information on the equations 
used to estimate deaths 
prevented or postponed from 
a treatment intervention or a 
reduction in CVD risk factors 
and provided all data sources 
that were used in the 
modelling  
Cost and QALYs were not 
Considered 
 
The model did not look at the  
reduction in CVD events, it was 
limited to avoided mortality 
 from CHD 
 
A recent expansion of the model 
(IMPACT 2) is available, however  
though online this model is a 
black box and a technical  
appendix was not available 
 
IMPACT2 is a DES model 
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revascularisation 
procedure 
 
Community dwelling 
patients with coronary 
artery disease 
 
Patients admitted to 
hospital with heart failure 
 
Community dwelling 
patients with heart 
failure 
 
Hypercholesterolaemic 
patients without CHD 
 
Hypertensive patients 
without CHD 
CHD Policy 
Analysis Model – 
Prevention 
component 
(Babad et al). (27) 
Discrete Event 
Simulation  
Age, sex, SBP, total 
cholesterol and smoking 
Onset of stable angina, 
unstable angina, 
myocardial infarction, 
sudden cardiac death, 
stroke death, other 
cardiovascular disease, 
cancer death and death 
from other or unknown 
cause      (potential to 
include HDl cholesterol) 
The model structure could be 
replicated – however no data 
inputs are given regarding 
treatment effectiveness  
Use of Framingham study 
to estimate baseline risk- 
recent studies have shown 
that QRISK is more suited 
to a UK population 
 
Computational 
requirements: Model was 
run in special software 
(POST, DELPHI 
framework).  This type of 
model would be 
computationally intensive 
to run in widely available 
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packages such as 
Microsoft Excel 
Department of 
Health Vascular 
checks economic 
model (34) 
Individual 
simulation  
Age, gender, townsend 
score, BMI, SBP, Smoking 
status, Total 
cholesterol/HDL ratio, 
record family history of 
CHD 
Not explicitly stated. 
Costs and health benefits 
applied in the model 
were based on published 
NICE guidance (PH1002, 
CG43, CG34 and TA94)  
The model inputs and data 
inputs are clear  
Cost and QALYs relating to 
interventions were not 
directly estimated: rather 
they were sourced from 
existing guidance and 
linked to the simulation 
outputs 
 
Requirement for a suitable 
large dataset to simulate 
can be expensive.  The 
Department of Health 
used the proprietary GP 
database QRESEARCH 
(approximate cost of 
dataset £15-20,000).   
BMI-body mass index, HDL- high-density lipoprotein, SBP- systolic blood pressure, DBP- diastolic blood pressure, CVD-cardiovascular disease, CHD-coronary 
heart disease, BP- blood pressure, AF- atrial fibrillation, TIA- transient ischemic attack, NICE-National Institute for Health and Care Excellence, DES-discrete 
event simulation, MI-myocardial infarction, ScHAAR-School of Health and Related Research, RISC- Rotterdam Ischemic disease and stroke model
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Section 2- Example of completed data extraction form  
 
Model name: Southampton Disease Model (CHD Policy Analysis Model) 'Treatment Model' 
Paper (Author, Year): The development of a simulation model of the treatment of coronary heart 
disease (Keith Cooper and Ruth Davies, 2002) 
Journal: Health Care Management Science 5, 259-267 
Model Details 
Model Structure: Discrete Event Simulation  
Model software: Patient orientated simulation technique (POST) software with a Delphi interface. 
Study Population & Setting: Individuals with stable angina, unstable angina or myocardial infarction 
(till age 85 or death).   
Purpose of Model: The model is used to evaluated revascularisation at a hospital level rather than 
population based.   Looks at progress of patients after a coronary event. 
Patient characteristics:  Given attributes of age, gender, vessel disease, time before cardiac death and 
time to age 85.  
Model Description: New patients enter the model with SA, UA or MI (proportion randomly 
determined using incidence rate of disease).  The following assumptions are employed: 
 Risk of non-cardiac death  
 Risk SA or UA leads to risk of MI 
 SA leads to risk of UA 
 Sampled time to event (MI, death, UA) depend on age and vessel disease 
 Risks of UA, MI, & death increase with age, severe vessel disease and with a history of previous 
myocardial infarctions.   
 Risks are independent of each other and are multiplied by baseline risks to change the 
projections of MI and death. 
 Time updated Gompertz distribution (hazard function) used to estimate time to event 
(includes relative risks from vessel disease, prior history and interventions) 
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Progression to health events:  Stable angina- Start in GP state receiving treatment (medical), assuming 
some have symptoms controlled and some not.  Some are transferred to outpatient’s investigations 
(now or in x years).  After outpatients, some join a waiting list for an angiogram (queue) and those 
who do not go to a medical treatment stage.  Vessel disease extent will determine next step after 
angiogram (can change this rule/input in simulation).  Patients can bypass graft, angioplasty.  
Incidence data from Health Survey for England and GP Morbidity data.  
Validation of model: validated cardiac deaths against mortality data from Office for National Statistics, 
based on death certificates.  Model did underestimate deaths in females. Authors surmised this was 
due to poor reporting of causes of death on certificates.  
Limitations Study (2002) does not mention the application of costs or QALYs and it looks at CHD events 
only.  The authors noted that the model will be developed further to link the outputs to costs and to 
include secondary prevention such as aspirin or anti-cholesterol agents and to link the treatment with 
the prevention model (Prevent model developed by Babad et al.)   
Summary- Discrete event simulation model for progress of patients after a coronary event.  Individuals 
have angina and can progress to unstable angina or myocardial infarction.  Changes in risks in one part 
can affect other parts of model.  This model did allow for resource constraints such as availability of 
tests  
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SupplementaryAppendix Figure 1 Illustration and details of Markov model developed for NICE clinical 
guidelines 181  
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